Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Condition:   Recurrent Nasopharyngeal Carcinoma
Intervention:   Drug: Nimotuzumab
Sponsors:   Fujian Cancer Hospital;   Sun Yat-sen University;   Jiangxi Provincial Cancer Hospital;   Zhejiang Cancer Hospital;   Fujian Medical University Union Hospital
Recruiting

https://ift.tt/2x3xN1J